What statin intensity and dose should be prescribed at discharge for a patient with an LDL cholesterol of 140 mg/dL and triglycerides of 348 mg/dL?

Statin Dosing at Discharge for LDL 140 mg/dL and Triglycerides 348 mg/dL

This patient requires high-intensity statin therapy at discharge—specifically atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily—regardless of whether this is for primary or secondary prevention, because the elevated triglycerides (348 mg/dL) combined with LDL 140 mg/dL places them at substantially increased cardiovascular risk. 1, 2

Recommended Statin Intensity and Specific Dosing

High-intensity statin therapy is mandatory and is defined as therapy expected to lower LDL-C by ≥50%. 3, 2

Preferred High-Intensity Options:

• Atorvastatin 40–80 mg once daily 1, 2
• Rosuvastatin 20–40 mg once daily 1, 2

Rationale for High-Intensity Therapy:

• The ACC/AHA guidelines recommend high-intensity statins for patients with established ASCVD (if this is secondary prevention) to achieve >75% of maximal statin potency. 1
• Even in primary prevention with LDL ≥70 mg/dL and additional risk factors, moderate-to-high intensity therapy is indicated. 3
• The elevated triglycerides (348 mg/dL) are a critical factor: all statins produce dose-dependent triglyceride reductions in hypertriglyceridemic patients (baseline TG >250 mg/dL), with reductions of 22–45% depending on dose and baseline TG level. 4, 5
• Higher-intensity statins produce proportionally greater triglyceride lowering—the triglyceride reduction correlates directly with LDL-C reduction (triglyceride/LDL-C ratio ~1.2 when baseline TG >250 mg/dL). 5

Target LDL-C Goals

• If this is secondary prevention (history of MI, stroke, or established ASCVD): Target LDL-C <55 mg/dL (or even <70 mg/dL as a minimum). 3, 1
• If this is primary prevention with ≥7.5% 10-year ASCVD risk: Target ≥50% LDL-C reduction from baseline. 3
• The ESC guidelines recommend achieving LDL-C <55 mg/dL in very high-risk patients and at least 50% reduction from baseline. 3

Critical Timing Consideration: Use Pre-Admission LDL-C as Reference

A common and dangerous pitfall is prescribing discharge statin therapy based on LDL-C measured during hospitalization after short-course high-intensity statin treatment. 6

• Statin treatment during admission can reduce LDL-C by 30% within 1–2 days and 40–45% in subsequent days. 6
• If you use the in-hospital LDL-C (which may already be suppressed by acute statin loading) as your reference, you will systematically under-prescribe lipid-lowering therapy at discharge. 6
• Only 30–37% of patients achieve LDL-C <55 mg/dL at 4–6 weeks post-discharge when discharge therapy is based on in-hospital LDL-C, versus the 88% who would theoretically achieve goal if basal (pre-admission) LDL-C were used. 6
• Always use the basal LDL-C level (140 mg/dL in this case) as your reference when calculating expected LDL-C reduction and tailoring discharge therapy. 6

Monitoring Strategy

• Obtain a fasting lipid panel 4–12 weeks after discharge to confirm adequate LDL-C reduction. 1, 7
• Check hepatic enzymes (AST, ALT) only if symptoms of hepatotoxicity develop—routine liver monitoring is not required. 7
• Assess for muscle symptoms (myalgia, weakness) at every follow-up visit. 7
• If LDL-C remains ≥70 mg/dL (secondary prevention) or ≥55 mg/dL (very high-risk) despite maximum tolerated statin, add ezetimibe 10 mg daily as adjunct therapy. 7

Special Considerations in Hypertriglyceridemia

• Atorvastatin may be preferred over rosuvastatin in this patient because atorvastatin produces greater triglyceride reductions (up to 28%) compared to other statins at equivalent LDL-lowering intensity. 2, 4
• Small dense LDL particles (LDL subclasses IIIa and IIIb) are elevated in hypertriglyceridemia and are highly atherogenic; high-dose atorvastatin (40–80 mg) significantly reduces these subclasses and increases LDL particle size. 4
• The triglyceride-lowering effect of statins is dose-dependent and only clinically significant when baseline TG >250 mg/dL, which applies to this patient (TG 348 mg/dL). 5

Common Pitfalls to Avoid

• Do not prescribe moderate-intensity statins (e.g., atorvastatin 10–20 mg, rosuvastatin 5–10 mg) in this patient—these doses will not achieve adequate LDL-C or triglyceride reduction. 2, 8
• Do not delay statin initiation until after discharge—patients who do not receive statins before hospital discharge are significantly less likely to be on appropriate therapy long-term. 1, 8
• Do not use simvastatin 80 mg—the FDA has issued a safety warning against initiating or titrating to this dose due to increased myopathy and rhabdomyolysis risk. 2
• Do not withhold statins due to mild transaminitis if the patient has NAFLD or metabolic syndrome (common with hypertriglyceridemia)—statins are safe and may be hepatoprotective in compensated liver disease. 7
• Do not focus solely on LDL-C levels—use the appropriate statin intensity based on risk category, not just target LDL-C values. 3

Evidence Quality and Nuances

• The recommendation for high-intensity statins in secondary prevention is supported by strong RCT evidence showing reductions in mortality, recurrent MI, and need for revascularization. 1
• However, in patients >75 years, moderate-intensity therapy may be more appropriate due to safety concerns and lack of incremental benefit from high-intensity therapy in this age group. 3, 9
• Real-world data from EUROASPIRE IV show that only 32.7% of CHD patients receive high-intensity statins and only 19.3% achieve LDL-C <70 mg/dL, indicating widespread undertreatment. 8